ASND
Ascendis Pharma A/S [ASND] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ASND Stock Summary
In the News
ASND Financial details
Company Rating
-
Market Cap
8.27B
Income
-481.45M
Revenue
266.72M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
879
Optionable
No
Shortable
Yes
Earnings
25 Apr 2024
P/E
-11.7
Forward P/E
-
PEG
6.58
P/S
43.73
P/B
-95.95
P/C
-
P/FCF
-11.6
Quick Ratio
2.38
Current Ratio
3.44
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-8.55
EPS next Y
-
EPS next Q
-
EPS this Y
-17.79%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
12.76%
Revenue last 5Y
81.95%
Revenue Q/Q
186.68%
EPS Q/Q
-46.88%
-
-
-
-
SMA20
2.32%
SMA50
4.74%
SMA100
19.96%
Inst Own
-
Inst Trans
-
ROA
-69%
ROE
-571%
ROC
-0.86%
Gross Margin
80%
Oper. Margin
-373%
Profit Margin
-396%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
66.03-161.0
52W High
+36.91%
52W Low
+233.97%
RSI
61.04
Rel Volume
3.83
Avg Volume
382.82K
Volume
1.47M
Perf Week
9.94%
Perf Month
8.2%
Perf Quarter
23.07%
Perf Half Y
29.05%
-
-
-
-
Beta
0.51
-
-
Volatility
6.93%, 6.29%
Prev Close
4.88%
Price
220.42
Change
8.21%
Company Profile
- Volume Average 382.82K
- Market Capitalization 8.27B
- Employee 879
- CEO Mr. Jan Moller Mikkelsen
- Headquarters Hellerup,DK
- IPO Date 2015-01-28
-
Website
https://ascendispharma.com 
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
